Patent · US Active

Antibodies against human CCN1 and uses thereof

US8207307B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Hendrik Knoetgen · Penzberg, DE
Hans-Willi Krell · Penzberg, DE
Sandra Miller · Munich, DE
Jens Niewoehner · Munich, DE
Dirk Ponsel · Germering, DE
Engin Toksoez · Munich, DE

Key dates

Filing date	Jun 3, 2010
Grant date	Jun 26, 2012
Priority date	—
Expiry date	Jul 9, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/03
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.